Multivariate analysis of hyperglycemia in extremely low birth weight infants

Soghier, Lamia; Brion, Luc P.

doi:10.1038/sj.jp.7211614

Cited by 6 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This lack of consensus on management, the high degree of variability in practice that has persisted over many years and the recent evidence of benefit of tight glycaemic control in adult populations has led us to conclude that the time is ripe for a randomised controlled trial of tight glycaemic control in VLBW neonates 16 . Towards this end, we have embarked upon a pilot study to assess feasibility of a protocol and to provide data that will enable us to perform a power calculation to estimate sample size.…”

Section: Discussionmentioning

confidence: 99%

Survey of the management of neonatal hyperglycaemia in Australasia

Alsweiler

Kuschel

Bloomfield

2007

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Survey of the management of neonatal hyperglycaemia in Australasia

Alsweiler

Kuschel

Bloomfield

2007

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

“…[12] A number of studies compared the effectiveness of continuous insulin infusion with reduction in dextrose concentration. [11] Overall they found that with …”

Section: Carbohydratementioning

confidence: 99%

Neonatal nutrition: a brief review

et al. 2008

View full text Add to dashboard Cite

show abstract

“…ELBWIs that develop hyperglycemia during the postnatal period show increased short-and long-term mortality rates. Early intervention to regulate blood glucose levels is essential because persistent hyperglycemia increases the risk of adverse events, such as sepsis, necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), retinopathy of prematurity (ROP) and death (1)(2)(3)(4).…”

Section: Introductionmentioning

confidence: 99%

Experience with enteral sulfonylurea monotherapy for extremely low birth weight infants with hyperglycemia

Nakagawa

Hirano

Inage

et al. 2022

Clin Pediatr Endocrinol

View full text Add to dashboard Cite

Limited data are available on the effects of enteral sulfonylurea (SU) monotherapy in extremely low birth weight infants (ELBWIs) with hyperglycemia. Therefore, we report our experience with enteral SU monotherapy for hyperglycemic ELBWIs. We retrospectively evaluated 11 hyperglycemic ELBWIs (seven male infants, median gestational age = 24.9 wk) who received SU between January 2016 and December 2019. Blood glucose (BG) levels were monitored before and after SU initiation and evaluated for the occurrence of adverse effects.We administered SU at a median of 15 d (interquartile range [IQR]: 12-20 d) after birth, with the median maximum dose of 0.2 mg/kg/d (IQR: 0.125-0.3 mg/kg/d). Hyperglycemia improved in all patients, and the target BG levels were achieved without severe side effects at a median of 6 d (IQR: 4-8.5 d) after initiation of treatment. The incidence of hypoglycemia during SU treatment was observed in 18 events per 1000 patient hours; however, the patients were asymptomatic. Based on these results, enteral SU monotherapy may be considered as an option for hyperglycemic ELBWIs. Highlights• This is the first case series of SU treatment in hyperglycemic ELBWIs• SU can be helpful in decreasing blood glucose levels in hyperglycemic ELBWIs• Further studies are required to evaluate efficacy and safety of SU in ELBWIs

show abstract

Multivariate analysis of hyperglycemia in extremely low birth weight infants

Cited by 6 publications

References 22 publications

Survey of the management of neonatal hyperglycaemia in Australasia

Survey of the management of neonatal hyperglycaemia in Australasia

Neonatal nutrition: a brief review

Experience with enteral sulfonylurea monotherapy for extremely low birth weight infants with hyperglycemia

Contact Info

Product

Resources

About